Contents
Quick Overview
- Shares of MRAM reached an annual peak of $23.10 on May 8, closing near $22.59 with approximately 437,000 shares changing hands
- A decade-long production agreement with Microchip Technology will bring U.S.-based MRAM manufacturing to an Oregon facility
- First-quarter earnings per share of $0.11 and revenue of $14.87M exceeded the $14.60M analyst projection
- Second-quarter 2026 EPS forecast ranges from $0.000 to $0.030; analyst rating averages Hold with $18.50 price target
- Top executives liquidated approximately $796K in shares during early May
Shares of Everspin Technologies (MRAM) reached a 52-week peak of $23.10 this past Friday, May 8, ultimately closing near $22.59. This represents a substantial premium over its 50-day moving average of $11.18 and its 200-day moving average of $10.63.
Everspin Technologies, Inc., MRAM
Trading volume for the session reached approximately 437,000 shares, notably higher than the previous closing price of $21.51.
The security has appreciated roughly 25% in recent weeks, primarily fueled by the announcement of a strategic manufacturing collaboration unveiled in April.
Strategic Partnership with Microchip Technology
Everspin revealed a 10-year collaboration with Microchip Technology on April 8, designed to manufacture MRAM and Tunnel Magnetoresistive (TMR) sensor components at Microchip’s fabrication plant in Oregon.
Under this arrangement, Everspin retains complete ownership of its intellectual property and manufacturing processes. The partnership also introduces ITAR-compliant wafer processing capabilities, crucial for serving defense and aerospace sectors.
Everspin’s current fabrication facility in Chandler, Arizona will remain operational alongside the new Oregon production line. Initial shipments from the Oregon facility are projected for the latter half of 2027.
The partnership includes provisions for extending the agreement in two-year intervals following the initial decade.
Strong Quarter, But Cautious Forward Outlook
First-quarter 2026 results showed earnings per share of $0.11 alongside revenue of $14.87 million, surpassing analyst projections of $14.60 million.
The company recorded a net margin of 0.50% with return on equity at 4.78%.
However, second-quarter 2026 projections paint a more conservative picture. Management’s EPS guidance of $0.000 to $0.030 represents an unusually broad and modest range, suggesting near-term uncertainty.
With a current market capitalization of $593 million and a PE ratio of 2,532, the company’s profitability trajectory remains in early development stages.
Mixed Signals from Analysts and Company Leadership
Analyst sentiment remains divided. Needham upgraded its price objective from $14.00 to $18.50 while reaffirming a Buy rating on April 30. Weiss Ratings maintained a Sell position in March. Wall Street Zen moved from Buy to Hold in February.
The consensus recommendation stands at Hold with an average price objective of $18.50—substantially below current trading levels.
Regarding insider activity, CEO Sanjeev Aggarwal liquidated 28,459 shares at $19.58 on May 4, generating approximately $557,000. This transaction reduced his holdings by 3.36%.
CFO William Earl Cooper disposed of 11,000 shares at $21.75 on May 6, totaling $239,250—representing a 6.39% decrease in his position.
Collectively, company insiders have sold roughly 60,448 shares valued at approximately $990,000 during the past three months.
Institutional investors hold 44.68% of outstanding shares, with multiple hedge funds establishing new positions in recent quarters, including Raymond James Financial, Kestra Advisory Services, and Occudo Quantitative Strategies.
The stock’s beta coefficient of 1.75 indicates elevated volatility relative to broader market indices.
